Your session is about to expire
← Back to Search
New Treatment for Lipoprotein Lipase Deficiency (AGL12 Trial)
AGL12 Trial Summary
This trial is testing a new treatment for lipoprotein lipase deficiency, which is a condition that causes high triglyceride levels in the blood. The new treatment is designed to help the body clear triglycerides from the blood.
AGL12 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAGL12 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AGL12 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Control subjects must have normal glucose and triglyceride levels.I am under 18 years old.You have been diagnosed with heparin-induced low platelet count before.I do not have liver, kidney diseases, or uncontrolled thyroid issues.I am taking medication that thins my blood or prevents blood clots.I have heart disease confirmed by my doctor and tests.I am not pregnant, breastfeeding, or planning to become pregnant.I am not on medication that affects my cholesterol or blood sugar, except for statins or metformin.I have had a major bleeding event in the past.You smoke more than one cigarette a day or drink more than two alcoholic beverages a day.I am between 18 and 75 years old.I have LPL deficiency with high fasting triglycerides and a confirmed LPL gene mutation.I am taking medication for high blood pressure and have LPL deficiency.
- Group 1: Control group- A0
- Group 2: LPLD group-A0
- Group 3: Control group-A1
- Group 4: LPLD group-A1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research opportunity include young adults?
"This trial is only looking for patients between 18-75 years of age. There are 4 other clinical trials that cater to patients below the age of majority and 45 trials for senior citizens."
What are researchers hoping to learn from this clinical trial?
"The purpose of this two-month study is to understand how dietary fat affects different organs. To do so, we will be measuring postprandial plasma NEFA turnover, Dietary fatty acid oxidation rate, and Total oxidation rate."
How many people are allowed to enroll in this clinical trial?
"The clinical trial is admitting 16 participants at 1 site."
Is this a groundbreaking or innovative trial?
"As of now, there are 44 ongoing clinical trials worldwide for this treatment across 210 cities and 23 countries. The first trial was held in 2006 and completed Phase 3 drug approval in the same year. 415 people participated in the trial sponsored by Ash Access Technology. In the years since 2006, 192 similar studies have been completed."
What are the typical conditions that this therapy is designed to address?
"This treatment is often used for medical devices, but it can also help patients with conditions like atrial fibrillation, sprains, and unstable angina pectoris."
Who can join this medical study?
"This study is looking for 16 individuals that meet the following criteria: age 18 to 75 years old, lipoprotein lipase, and a willingness to adhere to the protocol."
Are investigators looking for more participants at this time?
"Correct, the clinical trial is currently underway with a goal of recruiting 16 patients from 1 location. The information on clinicaltrials.gov shows that this trial was first posted on December 9th, 2019 and was last updated on September 27th, 2022."
Does this therapy have a history of being tested in other medical trials?
"As of right now, there are 44 on-going trials for this particular treatment. Out of these, 15 have reached Phase 3 status. Most studies related to this medication are based in Sherbrooke, Quebec; however, 388 research centres across the globe are currently investigating this topic."
Share this study with friends
Copy Link
Messenger